These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 35213367)
1. Novel Ultrasensitive Detection Technologies for the Identification of Early and Minimally Invasive Alzheimer's Disease Blood Biomarkers. Álvarez-Sánchez L; Peña-Bautista C; Baquero M; Cháfer-Pericás C J Alzheimers Dis; 2022; 86(3):1337-1369. PubMed ID: 35213367 [TBL] [Abstract][Full Text] [Related]
2. Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population. Wu X; Xiao Z; Yi J; Ding S; Gu H; Wu W; Luo J; Liang X; Zheng L; Xu H; Zhao Q; Ding D Clin Chem; 2021 Nov; 67(12):1628-1639. PubMed ID: 34662373 [TBL] [Abstract][Full Text] [Related]
3. Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis. Koychev I; Jansen K; Dette A; Shi L; Holling H J Alzheimers Dis; 2021; 79(1):177-195. PubMed ID: 33252080 [TBL] [Abstract][Full Text] [Related]
4. Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review. Cianflone A; Coppola L; Mirabelli P; Salvatore M J Alzheimers Dis; 2021; 84(1):393-407. PubMed ID: 34542072 [TBL] [Abstract][Full Text] [Related]
5. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
6. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase. Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521 [TBL] [Abstract][Full Text] [Related]
7. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Benedet AL; Brum WS; Hansson O; ; Karikari TK; Zimmer ER; Zetterberg H; Blennow K; Ashton NJ Alzheimers Res Ther; 2022 Feb; 14(1):26. PubMed ID: 35130933 [TBL] [Abstract][Full Text] [Related]
9. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776 [TBL] [Abstract][Full Text] [Related]
10. A Nanoplasmonic Biosensor for Ultrasensitive Detection of Alzheimer's Disease Biomarker Using a Chaotropic Agent. Kim H; Lee JU; Kim S; Song S; Sim SJ ACS Sens; 2019 Mar; 4(3):595-602. PubMed ID: 30747516 [TBL] [Abstract][Full Text] [Related]
11. [Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer's Dementia]. Hansen N; Rauter C; Wiltfang J Fortschr Neurol Psychiatr; 2022 Jul; 90(7-08):326-335. PubMed ID: 35858611 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies. Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009 [TBL] [Abstract][Full Text] [Related]
13. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403 [TBL] [Abstract][Full Text] [Related]
15. Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasma. Kim K; Kim MJ; Kim DW; Kim SY; Park S; Park CB Nat Commun; 2020 Jan; 11(1):119. PubMed ID: 31913282 [TBL] [Abstract][Full Text] [Related]
16. The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia. Santangelo R; Dell'Edera A; Sala A; Cecchetti G; Masserini F; Caso F; Pinto P; Leocani L; Falautano M; Passerini G; Martinelli V; Comi G; Perani D; Magnani G Curr Alzheimer Res; 2019; 16(7):587-595. PubMed ID: 31345148 [TBL] [Abstract][Full Text] [Related]
17. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease. Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M; JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873 [TBL] [Abstract][Full Text] [Related]
19. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Lantero Rodriguez J; Karikari TK; Suárez-Calvet M; Troakes C; King A; Emersic A; Aarsland D; Hye A; Zetterberg H; Blennow K; Ashton NJ Acta Neuropathol; 2020 Sep; 140(3):267-278. PubMed ID: 32720099 [TBL] [Abstract][Full Text] [Related]
20. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Qu Y; Ma YH; Huang YY; Ou YN; Shen XN; Chen SD; Dong Q; Tan L; Yu JT Neurosci Biobehav Rev; 2021 Sep; 128():479-486. PubMed ID: 34245759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]